Historical record - last NADAC effective date: 10/24/2018
Product Information
NEULASTA 6 MG/0.6 ML SYRINGE is a brand product labeled by Amgen Inc., priced at $10074.8571 per ML under NDC 55513019001. Its NADAC has been published 308 times since Nov 28, 2013.
Strength
6 mg/.6mL
Manufacturer
Amgen Inc.NDC
55513019001
Classification
Brand
Dosage Form
INJECTION
Route
SUBCUTANEOUS
Effective Date
10/24/2018
Active Ingredients
PEGFILGRASTIMApproval Type
Biologic (BLA)
FDA Application
BLA125031On Market Since
4/1/2002
Pharmacological Classes
Price Statistics
The NADAC for NEULASTA 6 MG/0.6 ML SYRINGE has been published 308 times since Nov 28, 2013, and over the history we have for it it has risen 53.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $10074.8571 per ML |
|---|---|
| All-time high | $10074.8571 (Oct 16, 2019) |
| All-time low | $6583.2050 (Nov 28, 2013) |
| Median price | $8660.4531 |
| Average price | $8576.9784 |
| Largest weekly change | +5.6% (Mar 16, 2016) |
| Weeks tracked | 308 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
+53.0%
Last surveyed Oct 16, 2019 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 68% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Amgen Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
pegfilgrastim market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Leukocyte Growth Factor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of NEULASTA 6 MG/0.6 ML SYRINGE?
The current National Average Drug Acquisition Cost (NADAC) for NEULASTA 6 MG/0.6 ML SYRINGE, manufactured by Amgen Inc., is $10074.8571 per ML (NDC 55513019001), effective Oct 16, 2019.
How has the price of NEULASTA 6 MG/0.6 ML SYRINGE changed over time?
Over the history we have for it, the NADAC for NEULASTA 6 MG/0.6 ML SYRINGE has risen 53.0%. It has been tracked across 308 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for NEULASTA 6 MG/0.6 ML SYRINGE?
Since Nov 28, 2013, the NADAC for NEULASTA 6 MG/0.6 ML SYRINGE has ranged from a low of $6583.2050 (Nov 28, 2013) to a high of $10074.8571 (Oct 16, 2019), with a median of $8660.4531 per ML.
Are there cheaper alternatives to NEULASTA 6 MG/0.6 ML SYRINGE?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, FULPHILA 6 MG/0.6 ML SYRINGE, is $3185.9367 per ML — about 68% below NEULASTA 6 MG/0.6 ML SYRINGE.
Who manufactures NEULASTA 6 MG/0.6 ML SYRINGE?
NEULASTA 6 MG/0.6 ML SYRINGE (NDC 55513019001) is labeled by Amgen Inc., and CMS classifies it as a brand product.